State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi, 214122, Jiangsu, China.
School of Food Science and Technology, Jiangnan University, Wuxi, 214122, Jiangsu, China.
Eur J Nutr. 2020 Oct;59(7):3069-3081. doi: 10.1007/s00394-019-02145-8. Epub 2019 Nov 30.
Emerging studies have reported gut microbial composition plays a key role in alleviating AD clinical symptoms during the probiotic intervention, but the correlation among clinical symptoms, immune responses and gut microbial alteration needs to be explored. Therefore, the objective was to investigate the correlation during Bifidobacterium adolescentis intervention in DNFB-induced AD mice.
The mice were randomly divided into nine groups and fed B. adolescentis for 3 weeks. At the end of the experiment, clinical and immune indicators were assessed. Flow cytometry was performed to explore the effect of B. adolescentis on regulatory T cells in the spleen. V3-V4 region of the 16S ribosomal RNA (rRNA) gene was sequenced to evaluate changes in the gut microbiota.
Bifidobacteria adolescentis treatments reduced ear and skin thickness and suppressed eosinophils and mast cells infiltration. Th1- and Th2-type responses were regulated and the Tregs population was promoted in the spleen by B. adolescentis treatments. Bifidobacteria adolescentis increased the relative abundance of Lactobacillus but decrease Dorea and Pediococcus. Propionic and butyric acids were increased but isovaleric acid was decreased by B. adolescentis treatment. Besides, the functional modules, such as fatty acid biosynthesis, antigen processing and presentation were upregulated by B. adolescentis Ad1 treatment compared to the DNFB group.
Collectively, these results imply that B. adolescentis with the role of immunomodulation promotes Treg differentiation and suppresses Th2 responses, and increases the proportion of Lactobacillus that is positively correlated to increase in propionic acid production, and thus has the potential for AD amelioration.
越来越多的研究表明，肠道微生物组成在益生菌干预缓解 AD 临床症状中起着关键作用，但临床症状、免疫反应和肠道微生物变化之间的相关性仍需探索。因此，本研究旨在探讨双歧杆菌干预 DNFB 诱导 AD 小鼠过程中的相关性。
将小鼠随机分为 9 组，连续 3 周灌胃双歧杆菌。实验结束时，评估临床和免疫指标。采用流式细胞术研究双歧杆菌对脾脏调节性 T 细胞的影响。通过 16S rRNA 基因 V3-V4 区测序评估肠道微生物群的变化。
双歧杆菌治疗可降低耳和皮肤厚度，抑制嗜酸性粒细胞和肥大细胞浸润。双歧杆菌治疗可调节 Th1 和 Th2 型反应，并促进脾脏中 Treg 细胞的增殖。双歧杆菌增加了乳杆菌的相对丰度，降低了 Dorea 和 Pediococcus 的相对丰度。双歧杆菌治疗增加了丙酸和丁酸的含量，降低了异戊酸的含量。此外，双歧杆菌 Ad1 治疗与 DNFB 组相比，上调了脂肪酸生物合成、抗原加工和呈递等功能模块。
综上所述，这些结果表明，双歧杆菌具有免疫调节作用，可促进 Treg 分化，抑制 Th2 反应，并增加与丙酸产量增加呈正相关的乳杆菌比例，从而具有改善 AD 的潜力。
